Emergent BioSolutions | EBS - Current Liabilities

Stock Price
10.93
Daily Change
-0.06 -0.55%
Monthly
-4.96%
Yearly
41.76%
Q1 Forecast
10.65

Emergent BioSolutions reported $651.3M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Akebia Therapeutics USD 133.38M 14.66M Sep/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 182.23M 3.71M Sep/2025
ANI Pharmaceuticals USD 270.56M 33.72M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Coherus Biosciences USD 372.3M 108.67M Sep/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Exact Sciences USD 641.15M 56.89M Dec/2025
Exelixis USD 405.64M 31.86M Dec/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
Lexicon Pharmaceuticals USD 34.84M 75.86M Jun/2025
Lonza CHF 3.58B 970M Dec/2024
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Myriad Genetics USD 148M 51.9M Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Pacira USD 107.08M 206.09M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Xoma USD 28.3M 6.81M Sep/2025